Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 13/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 13/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690816 | 0.82 | NPC1 (0.82) | NPC1RAB9AKMT2A | |
| SCHEMBL19002583 | 0.80 | RAB9A (0.58) | NPC1RAB9AKMT2A | |
| SCHEMBL19049387 | 0.80 | HSD17B2 (0.61) | HSD17B1HSD17B2 | |
| SCHEMBL19002595 | 0.80 | HSD17B2 (0.55) | HSD17B1HSD17B2NPC1RAB9AAOC3 | |
| SCHEMBL19002486 | 0.80 | MEP1A (0.51) | HSD17B1HSD17B2NPC1RAB9AKMT2A | |
| SCHEMBL17882188 | 0.79 | RIPK1 (0.72) | HSD17B1HSD17B2 | |
| SCHEMBL13639156 | 0.76 | PPARA (0.57) | NPC1RAB9AKMT2A | |
| SCHEMBL9416596 | 0.76 | HSD17B2 (0.83) | HSD17B1HSD17B2KMT2A | |
| SCHEMBL14753662 | 0.74 | RIPK1 (0.66) | NPC1RAB9AKMT2A | |
| SCHEMBL31126662 | 0.74 | ALDH1A1 (0.54) | HSD17B1HSD17B2DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HSD17B1 1693/4885HSD17B2 1736/4885NPC1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.